Welcome to our dedicated page for Harrow Health SEC filings (Ticker: HROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harrow, Inc. (HROW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. Harrow is an ophthalmic-focused pharmaceutical company whose common stock trades on the Nasdaq Stock Market, and its filings offer detailed information about its financial condition, capital structure, and material corporate events.
Harrow’s current reports on Form 8-K include disclosures about quarterly financial results, investor presentations, credit agreements, leadership changes at subsidiaries, and business development transactions. For example, recent 8-K filings describe the announcement of financial results for the period ended September 30, 2025, the entry into and terms of a senior secured revolving credit facility with a commercial bank, and the agreement to acquire, and subsequent completion of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies.
The company’s filings also document capital markets and debt activities. Harrow has reported the pricing of senior unsecured notes due 2030 in a private offering and related plans to use the proceeds to repay existing debt and redeem previously issued senior notes. Separate Form 25 filings by the Nasdaq Stock Market LLC show the removal from listing and registration of Harrow’s 8.625% senior notes due 2026 and 11.875% senior notes due 2027.
Through Stock Titan, users can follow Harrow’s 10-K annual reports, 10-Q quarterly reports, and 8-K current reports as they are made available on EDGAR. AI-powered summaries help explain the key points in these documents, including revenue trends, operating results, debt arrangements, and the terms of material agreements such as merger agreements and credit facilities. The filings page also surfaces information relevant to equity and debt investors, including unregistered sales of equity securities disclosed in connection with milestone-based consideration for acquisitions.
For investors analyzing Harrow’s ophthalmic and procedural sedation strategy, the SEC filings provide primary-source detail on transaction structures, milestone obligations, and financial covenants. Stock Titan’s tools are designed to make these complex filings easier to review by highlighting important sections and presenting concise explanations of the underlying disclosures.
Opaleye Management Inc., a 10% owner of HARROW, INC., reported open-market sales of Harrow common stock through affiliated entities on March 3 and 4, 2026.
Opaleye, L.P. sold 59,000 and 134,000 shares at weighted average prices of
HARROW, INC. insider Opaleye Management Inc., as portfolio manager of a separately managed account, reported an open-market sale of 5,000 shares of common stock on February 27, 2026 at a price of $54.18 per share.
After this sale, the managed account held 65,000 shares indirectly attributed to Opaleye. A separate holding of 3,815,000 shares is owned directly by Opaleye, L.P., for which Opaleye Management Inc. is the investment manager. Opaleye Management Inc. disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest.
Harrow, Inc. outlines its position as a North American leader in ophthalmic disease management, combining branded pharmaceuticals with its ImprimisRx compounding business. The company markets numerous FDA-approved eye products and is building a late-stage pipeline, highlighted by MELT-300 for non‑IV, non‑opioid sublingual procedural sedation.
MELT-300 has completed Phase 3 under a Special Protocol Assessment, with an NDA planned for the first half of 2027 and a targeted U.S. launch in the second half of 2028. Harrow also plans mid‑2026 and mid‑2027 launches for BYOOVIZ and OPUVIZ biosimilars and BYQLOVI for post‑operative inflammation.
In November 2025, Harrow acquired the remaining equity of Melt Pharmaceuticals for an initial $4.3 million cash payment plus potential milestone-based cash and equity tied to MELT‑300 approval, reimbursement, and sales. Research and development expenses rose to $20.94 million in 2025 from $12.23 million in 2024 and $6.652 million in 2023, reflecting increased investment in pipeline assets and the Melt acquisition.
The company reports two segments—Branded and ImprimisRx—both U.S.-based, and had 373 employees as of February 25, 2026. Harrow emphasizes regulatory and reimbursement complexity, competition from larger pharmaceutical and biosimilar players, and evolving federal and state pharmacy rules, especially around its 503A/503B compounding facilities, as key risks to growth and profitability.
Harrow, Inc. reported strong growth for Q4 and full-year 2025 and issued 2026 guidance. Quarterly revenue reached $89.1 million, up 33% from $66.8 million, while full-year revenue rose 36% to $272.3 million from $199.6 million. Q4 GAAP net income was $6.6 million, though the company posted a $5.1 million net loss for 2025. Adjusted EBITDA grew to $24.2 million in Q4 and $61.9 million for the year. Operating cash flow swung to a positive $43.9 million in 2025 from $(22.2) million in 2024, and cash and cash equivalents were $72.9 million at year-end. Management highlighted strong momentum in key ophthalmic brands VEVYE, IHEEZO and TRIESENCE and outlined plans to expand sales teams and invest in growth initiatives. For 2026, Harrow guides to $350–$365 million in revenue and $80–$100 million in Adjusted EBITDA, with results expected to be more heavily weighted to the second half of the year.
Harrow, Inc.’s chief commercial officer, Patrick William Sullivan, received two new restricted stock unit awards. On 01/30/2026 he was granted 25,000 RSUs and 15,000 RSUs under the company’s 2025 Incentive and Awards Plan, each RSU representing one share of Harrow common stock upon vesting.
The 25,000 RSUs have a five-year term and vest only if Harrow’s revenue reaches
Harrow, Inc. filed a Form 3 for Chief Commercial Officer Patrick William Sullivan, reporting a stock option over 30,000 shares of common stock. The option has an exercise price of $39 per share and expires on September 1, 2035.
According to the vesting schedule, 25% of the option shares vest on the one-year anniversary of the grant date. The remaining shares vest in 12 equal quarterly installments over the following three years, becoming fully vested and exercisable on September 1, 2029. The option is held directly.
Harrow, Inc. filed an update covering its outlook and leadership team. The company reaffirmed its full-year 2025 revenue guidance in a range of $270 million to $280 million, signaling no change to its previously communicated expectations.
Harrow also appointed Patrick W. Sullivan as Chief Commercial Officer, effective January 30, 2026. He brings more than 25 years of commercial leadership experience from roles at Corium Therapeutics, AstraZeneca, Shire, Adolor, Novartis, and Bayer. Under his offer letter, Sullivan will receive a $425,000 annual base salary, a target annual bonus equal to 40% of base compensation, and 40,000 restricted stock units. Of these, 25,000 RSUs vest if Harrow’s revenue reaches $230,000,000 in a calendar quarterly period, and 15,000 RSUs vest three years from the award date.
Harrow, Inc. insider Opaleye Management Inc., a 10% owner, reported an indirect sale of Harrow common stock. On January 6, 2026, a separately managed account for which Opaleye acts as portfolio manager sold 20,000 shares of common stock at a weighted average price of $53.3457 per share. After this transaction, the managed account held 70,000 shares indirectly attributed to Opaleye. Separately, 3,815,000 shares were reported as owned by Opaleye, L.P., for which Opaleye Management Inc. is the investment manager. Opaleye Management Inc. states it may be deemed a beneficial owner through these roles but disclaims beneficial ownership beyond its pecuniary interest.
Harrow, Inc. reported that its president and CFO, Andrew R. Boll, exercised 60,000 stock options on 12/12/2025 at an exercise price of $3.95 per share, receiving the same number of common shares.
The options were originally granted on April 1, 2016 under the company’s 2007 Stock Incentive and Awards Plan and vested quarterly over three years. In connection with the exercise, 26,665 shares were withheld to cover the exercise price and tax liability, and the filing states this withholding did not involve any market sales or other market transactions. After these transactions, Boll beneficially owns 811,179 shares of Harrow common stock directly.
Harrow, Inc.'s chief executive officer and director Mark L. Baum reported exercising stock options for 180,000 shares of common stock at $3.95 per share.
After this option exercise and the withholding of 79,994 shares to satisfy the exercise price and tax obligations, he directly owns 2,986,130 shares of Harrow common stock. The company notes that the share withholding did not involve any market sales or other market transactions.